Introduction
============

Circulating tumour cells (CTC) have been shown to play a major role in breast cancer (BC) tumour biology and may have a prognostic value in patients with metastatic disease \[[@B1]\] Primary tumour architectural characteristics may define its ability to metastize \[[@B2],[@B45]-[@B48]\]. Weak cell-cell connections lead to the dissemination of tumour cells via blood and lymph vessels \[[@B3]\]. Tumour cells entering the circulation depend on the organ microenvironment in order to be able to colonize tissues and to proliferate \[[@B4]-[@B7]\].

Altered gene expression is held responsible for a transformed behaviour of tumour tissue \[[@B8]-[@B11]\] and may distinguish CTC from healthy cells \[[@B12],[@B13]\]. However, it remains unclear which genes allow a specific detection of CTC. Furthermore, inter-individual variations in gene expression levels due to certain genetic polymorphism additionally challenge these investigations.

The relatively small amount of CTC in PB of cancer patients led to the development of improved detection systems and cell enrichment \[[@B1],[@B14]\]. Several approaches of immunomagnetic enrichment of CTC in samples of PB have been investigated \[[@B15]-[@B17]\]. Beads coated with monoclonal antibodies (mcAb) against epithelial surface proteins achieve a precise detection and extraction of epithelial and carcinoma cells from PB. Subsequently, enriched CTC can be detected by reverse transcriptase polymerase chain reaction (RTPCR) of altered marker genes putatively supposed to be tumour predictive. Several investigations have analysed various genetic markers to detect CTC.

A French study showed an over expression of *Mucin 1*(*muc-1*), a gene coding for a polymorphic epithelial surface phosphoprotein. This study included both patients with benign breast disease and advanced BC and indicated a significant correlation between the presence of *muc1*-positive cells and tumour staging \[[@B18]\]. These findings were reproduced by Felton et al. showing similar results in patients with advanced disease \[[@B19]\].

*ga733.3*(*TACSTD1, Ep-CAM*), a gene responsible for epithelial cell-cell adhesion by encoding a surface glycoprotein, is regarded as being present exclusively on epithelial cells \[[@B20]\]. Its use as a tumour marker has been controversially discussed \[[@B21]\]. Nevertheless Rao et al. \[[@B22]\] could demonstrate a decreased expression of *ga733.2*in CTC as compared to primary tumour cells. This might indicate that decreased levels of this protein are crucial to the loss of cell adhesion which allows tumour cell to access the circulation. Notably Watson et al. documented an overexpression of SCGB2A2 (*mammaglobin 1; MGB-1*), a polypeptide member of the uteroglobin family, in BC \[[@B23],[@B24]\]. *Mammaglobin1*-RT-PCR determination in PB was suggested as an adjunct to serum tumour markers by Lin et al. since the sensitivity sole *mgb1*in RT-PCR assays was considered as not convincing. Further studies compared the positivity of fresh BC tissue and PB \[[@B25]\]. Furthermore, a correlation between the frequency of *mgb1*overexpression in PB and the tumour stage of BC was described by Cerveira et al. \[[@B26]\].

Ghadersohi et al. described a strong expression of *spdef*in RT-PCR assays of BC tissues. Further investigations showed a superior tumour-association of this marker as compared to other cancer-associated molecules \[[@B27]-[@B30]\].

The purpose of the present study was to characterize CTC in PB of BC patients applying a commercially available system that targets the above mentioned genes.

Material and methods
====================

This study was reviewed and approved by the institutional human subjects committee. BC patients and healthy individuals serving as controls provided informed-consent to all procedures.

Study design
------------

Our study included 63 BC patients and 14 healthy controls. Patients ages ranged from 33 to 81 years with a median of 60 years. The age of controls varied between 24 and 61 with a median of 41.5 years. Fifty patients presented with first diagnosis (FD) of BC and 13 had relapse disease (RD) at the time of the PB collection. Disease staging according to the *American Joint Committee on Cancer*(*AJCC*) is summarized in Table [1](#T1){ref-type="table"}. The median time interval between surgical treatment and study enrollment was 2.5 months for FD and 60 months for relapse disease (RD).

###### 

Clinical Staging

  G     1    2       3       X      Σ
  ----- ---- ------- ------- ------ ------
  FD    4    25      19      2      50
  (%)   8%   50%     38%     4%     100%
  RD    0    8       4       1      13
  (%)   0%   61.5%   30.8%   7.7%   100%

63 breast cancer patients presenting with First Diagnosis (FD) or Relapse Disease (RD) were enrolled in this study. G represents disease staging according to the American Joint Committee on Cancer (AJCC).

Cell separation
---------------

Venous blood samples were collected in EDTA Vacutainer Tubes (*Becton Dickinson, NJ USA*) and processed within 2 hours using the immunomagnetic separation technique *Adnagen Breast Cancer Select Kit*(*ABCS*) (*Adnagen, Langenhagen, Germany*) following the manufacturer\'s instructions. This technique is based on an immunological selection of shedded non-haematological cells using antibodies, directed against epithelial and probably malignant surface antigens. Briefly, a combination of antibodies is loaded with magnetic particles and preserved in sodium-acid. Antibodies against *ga733.3*and two different antibodies against epitopes of *mucin-1*were used.

Before applying the blood samples, the immunomagnetic beads underwent three washing steps in a 1.5 ml tube using 1 ml PBS (*Gibco Invitrogen, Karlsruhe Germany*). Each step contained a bead separation in a magnetic bar system (*MPC-S of Dynal*). Subsequently 100 μl of immunomagnetic beads were added to 5 ml of blood samples without any additions. Samples, including beads, were inserted in a tube rotator for 2 hours at 20 rounds per minute (rpm) and room temperature (RT).

Using a larger magnetic bar system (*MPC-L of Dynal Invitrogen, Karlsruhe Germany*), bead-loaded cells were accumulated on the *MPC-L*side. Subsequently, supernatants were removed cautiously and PBS (5 ml) was added. PBS addition, *MPC-L*hold and removing of supernatants were repeated two times. At the end of this step, bead-cell-complexes were resuspended in 1 ml of PBS and inserted in *MPC-S*. Supernatants were removed once more and complexes were resuspended in 200 μl of *ABCS*lysis/binding buffer. Finally, samples were inserted into *MPC-S*again. This time, supernatants, including cell lysates with native mRNA, were saved and stored at -20°C.

*ABCD*was applied for RT and PCR steps of stored cell lysates. This kit contains lysis/binding buffer, oligo(dT)-25 beads, buffers A and B, tris-HCl and Primermix. Additionally used kits included *Sensiscript Reverse Transcription Kit*and *HotStarTaq Mastermix Kit*(*Qiagen*)and *Recombinant RNAsin*(RNAse-Inhibitor *Promega*).

Briefly, oligo(dT)-coated beads (*ABCD Dynabeads*), targeting certain mRNA, were inserted in MPC-S and supernatants were removed. Beads were washed in lysis/binding buffer. This step was repeated once and 20 μl of dynabead was aliquoted subsequently to each sample of cell lysates. The mix of cell lysates and *dynabeads*was placed on a tube rotator for 10 minutes at 20 rpm and RT. Samples were inserted in *MPC-S*and supernatants were removed.

Next, samples were washed in series with buffer A, B and tris-HCl and inserted in *MPC-S*each time. Supernatants were removed. Washing steps with buffer A and B were processed twice, whereas tris-HCl was applied once.

After the final elimination of supernatants, we resuspended mRNA-bead-complexes in 29.5 μl RNAsefree water and incubated them in a thermomixer for 5 minutes at 650 rpm and 50°C.

Reverse transcription (RT)
--------------------------

Prepared RT-mix consisted of 4 μl 10 × buffer RT, 4 μl dNTPs, 2 μl RT (*Qiagen, Hilden Germany*) and 0.5 μl RNAse inhibitor (*Promega, Mannheim Germany*)for each sample of 29.5 μl mRNA/bead-complexes. RNAsefree water was used as control. Transcription was performed in a thermocycler (*Perkin Elmer*9600; 2°C/second) with following program:

37°C for 60 minutes - reverse transcriptase step

93°C for 5 minutes - inactivation step

cDNA suspension was stored on ice.

Multiplex PCR
-------------

Multiplex PCR (mPCR) was executed using 25 μl of *Hotstar Taq Mastermix*(*Qiagen, Hilden-Germany*), 13 μl distilled water, 4 μl *PrimerMix Breast Detect*(*ABCD*)and 8 μl of cDNA suspension, RT-control, water as negative control or positive control (*ABCD*) respectively. Primermix was a threefold combination of primers for *ga733.2*(383 bp), *muc-1*(293 bp), *c-erbB2*(270 bp) and β-actin (114 bp) as control gene^41^. The total volume of 50 μl was inserted in a thermocycler (*Perkin Elmer 9600; 2°C/second*) and PCR was performed with 2°C/second according to the following program:

1\. 95°C for 15 minutes - Taq activation

2\. 94°C for 1 minute

3\. 60°C for 1 minute

4\. 72°C for 1 minute

5\. 72°C for 10 minutes - final elongation

6\. 4°C

Steps 2 to 4 were repeated for 35 cycles. Finally, DNA suspensions were stored at -20°C. PCR products were analyzed in bioanalyzer (*2100 - bioanalyzer Agilent, CA, USA*) via DNA chips (version 25-1000 bp). Results were registered according to the fluorescence and via conversion in absolute cDNA concentration (ng/μl). As mentioned previously β-Actin was chosen as house keeping gene.

Realtime-PCR
------------

The expression of *c-erbB2, mgb1 and spdef*was determined quantitatively using high throughput real-time RT-PCR applying an ABI PRISM^®^7900 HT cycler (*AME Bioscience, Toroed Norway*). *GUSBL1*(*beta-like glucuronidase 1*) was chosen as housekeeping gene. Probes were ordered as *\"ready to order\" primer probe TaqMan gene expression assays, (*Hs00170433_m1 for c-erbB2, HS00267190_m1 for *mgb1*, HS0017942_m1 for *spdef, Applied Biosystems*, CA, USA). Each assay contained a pair of amplification primers and an additional Taq-Man MGB oligonucleotide probes with a 6-FAM fluorescent dye linked to the 5\'end and one dark quencher on the 3\'end with a minor groove binder protein, increasing the probe melting temperature (*Tm*). Genes were selected according to frequently appearing gene expressions in our previous data (*Affymetrix Chip HgU133A*, 22283 genes in 83 breast cancer profiles vs 5 normal breast profiles) \[[@B31]\].

The PCR was run in a 96-well plates at a total volumes of 25 μl, containing the TaqMan Universal PCR Master Mix (dNTP, buffer, ROX and the AmpliTaq-Gold). The default thermal cycling protocol (as recommended by ABI) was used for all target genes and the reference gene (initial step of 15 min at 95°C for the activation of the AmpliTaqGold and an amplification cycle of 15 sec at 95°C and 1 min at 60°C for 40 cycles). Genes were quantified by determination of a threshold cycle numbers (ct). One common threshold was specified manually within the early exponential phase of fluorescence increase and it was used for all genes within one experiment. \'Transcriptase-minus\' and \'water-only\' controls were included.

The *Her-2/neu*status of 84.1% of our patients was determined routinely using immunhistochemistry (antibody against *Her-2/neu: polyclonal DAKO 1: 250*). Staining results are classified into four levels according to the manufacturer\'s recommendation. Highly positive synthesis of *Her-2/neu*(≥ 2+) was observed in 20 cases of BC (20/53; 37.7%).

Statistical evaluation
----------------------

Statistical evaluation was performed using SPSS 11.5 for Windows (Microsoft Corp., SA, USA). Specific amplifications both in mPCR and realtime-PCR were registered in units specified for each gene and each group of patients separately. Results were recorded in dichotomized values. The threshold of dichotomized compilation was predetermined at 0.1 ng/μl for mPCR according to manufacturer\'s recommendation. Realtime-PCR results with (ct) values below 41 cycles were considered as positive. Afterwards, we searched for correlations between cases of FD, RD and healthy participants. Besides single gene evaluations‚, these searches also included multiple gene evaluations. Single-positive results were defined as samples that featured positive expressions for one gene, whereas twofold-positive results were defined as samples that featured positive expressions of at least two genes \[[@B32]\]. Correlations were checked either by Pearson\'s two-sided χ^2^-test for dichotomized values or by Pearson\'s bivariate correlation for values with two thresholds. The level of significance was determined as p \< 0.05.

Results
=======

Expression levels of *ga733.2, muc-1*and *c-erbB2*in PB through mPCR
--------------------------------------------------------------------

Positive absolute PCR products of BC patients ranged from 0.1 to 8.4 ng/ml for *ga733.3*, from 0.12 to 6.3 ng/ml for *muc-1*and from 0.13 to 1.1 ng/ml for *c-erbB2*.

In the population of FD we observed specific amplifications for *ga733.3*(5/50; 10%), *muc-1*(6/50; 12%) and *c-erbB2*(7/50; 14%).

Cases of RD exposed overexpression rates for *ga733.3*(3/13; 23.1%), *muc-1*(4/13; 30.8%) and *c-erbB2*(1/13; 7.7%). Healthy controls showed positive expressions for *ga733.3*(1/14; 7.1%), *muc-1*(1/14; 7.1%) and *c-erbB2*(7/14; 50%) (Figure [1](#F1){ref-type="fig"}).

![***ga733.3*and *muc-1*expression**. Multiplex pcr analyses of *ga733.2*and *muc-1*in peripheral blood. The \"overall\" panel refers to the patients with First Diagnosis (FD) and Relapse Disease (RD) excluding healthy controls.](2047-783X-14-10-426-1){#F1}

Expression levels of *mgb-1, spdef*and *c-erbB2*in PB through RT-PCR
--------------------------------------------------------------------

4 samples of FD and 2 cases of RD had neither *mgb1*specific nor non-specific transcription and were excluded from further examination. The same lack of transcription was found in 2 cases of FD and 1 case of RD concerning *spdef*. Hence we continued our investigation including 55 patients (44 FD and 11 RD cases) concerning *mgb1*and 58 patients (46 FD and 12 RD cases) concerning *spdef*. Results of remaining products of patients ranged from 28 cycles to 39.5 cycles for *mgb1*and from 29.4 cycles to 40.9 cycles for *spdef*. Specific signals (\< 41 ct) for *mgb1*were observed in 2/44 (4.5%) cases of FD and 3/11 (27.3%) cases of RD, whereas this value was 0/14 in healthy controls. spdef was detectable in 5/46 (10.9%) cases of FD, in 2/12 (16.7%) cases of RD and in 0/14 healthy controls, respectively. *C-erbB2*expression was found in 11/50 (22%) cases of FD, in 5/13 (38.5%) cases of RD and in 10/14 (71.4%) healthy controls. Results ranged from 39.9 cycles to 33.5 cycles (Figure [2](#F2){ref-type="fig"}).

![***spdef*and *mgb1*expression**. Positivity for *spdef*and mammaglobin1 in peripheral blood through RT-PCR. The \"overall\" panel refers to the patients with First Diagnosis (FD) and Relapse Disease (RD), excluding healthy controls.](2047-783X-14-10-426-2){#F2}

View of multiple-positive cases
-------------------------------

The analyses of simultaneous gene expressions of *ga733.3, muc-1, spdef*and *mgb1*revealed 15 cases of BC with a positive expression of at least one of these genes. As results of *mgb1*were available in 55 cases, we limited this part of the investigation to this cohort of patients. Nine out of 44 positive cases were found in FD cases (9/44; 20.5%) and 6 out of 11 in RD cases (6/11; 54.5%).

View of simple-positive expression of the gene profile *ga733.2*\**muc-1*\**mgb1*\**spdef*
------------------------------------------------------------------------------------------

The 15 participants of the BC group (15/55; 27.3%) had at least one positive expression of the gene pattern GA7 *ga733.3*\**muc-1*\**mgb1*\**spdef*. Nine cases (20.5%) belonged to the FD cohort and 6 (54.5%) to RD cohort. Healthy controls also demonstrated positive results in 2 cases (14.3%) (Figure [3](#F3){ref-type="fig"}).

![***ga733.2*\**muc-1*\**mgb1*\**spdef*expression**. Simple positive or two-fold positivity for the gene pattern *ga733.2*\**muc-1*\**mgb1*\**spdef*. The \"overall\" panel refers to the patients with First Diagnosis (FD) and Relapse Disease (RD), excluding healthy controls.](2047-783X-14-10-426-3){#F3}

View of twofold-positive expression of the gene profile *ga733.3*\**muc-1*\**mgb1*\**spdef*
-------------------------------------------------------------------------------------------

Regarding at least two positive gene expressions in the pattern specified above, 10 cases (18.2%) of BC patients and no healthy controls fulfilled this criterion. 6 positive cases were seen in the group of FD (6/44; 13.6%) and 4 in the group of RD (4/11; 36.4%) (Figure [3](#F3){ref-type="fig"}).

Correlation of expression results to *Her-2/neu*level via IHC
-------------------------------------------------------------

Since we did not detect any significant correlation of *Her-2/neu*status and *c-erbB2*mRNA in the results of our mPCR and realtime-PCR analyses, the investigation comparing *Her-2/neu*to other genes and respective gene profiles did not reach any significance.

Discussion
==========

Today there is a growing interest in the gene characterization of CTC in BC, since it may provide important information on the mechanisms for tumour cell metastasation. We analyzed PB samples of BC patients presenting at our gynaecology department. The goal of our study was to determine marker genes with a high sensitivity for the detection of CTC. For this aim, we selected tools to detect CTC and to amplify DNA of predetermined genes, which are potentially overexpressed in tumour cells. Based on data provided by recent studies we used an immunomagnetic method to select circulating carcinoma cells \[[@B33],[@B34]\]. An adverse effect on gene expression by application of direct immunomagnetic enrichment was excluded \[[@B35]\].

Several studies have described *muc-1, c-erbB2*and *mgb1*as putative markers in BC. Yet, our not-preselected group of BC patients revealed a markedly lower overall expression of *muc-1*as compared to other recent investigations \[[@B14]-[@B36]\]. Yet, tour results concerning *mgb1*match those of Grunewald et al. \[[@B37]\]. Nevertheless higher expressions of *mgb1*(36.6%) in all stages of BC as compared to healthy controls were described by Lin et al. \[[@B38]\].

Additionally our study investigated *ga733.3*and *spdef*, which have not been described commonly in BC cases, but which do possess putative marker characteristics \[[@B20],[@B28]-[@B30],[@B39]\]. Notably, *ga733.3*and *spdef*showed nearly the same overall frequency of overexpression as the above mentioned cancer-associated marker genes. To the best of our knowledge, investigations of *spdef*in PB applying RT-and realtime PCR analyses have not been described in the literature, yet. Remarkably, the use of *ga733.3*as marker was controversially discussed in recent studies due to its minimal basal expression in hematopoietic cells \[[@B21]\]. *ga733.3*transcribes the surface molecule Ep-CAM in epithelial cells and serves as target molecule in immunomagnetic procedures of cell detection \[[@B41],[@B42]\]. Thus, our study includes both Ep-CAM as immunomagnetic target transcript and *ga733.3*as investigated gene using mPCR.

Comparisons of controls and BC patient groups revealed an increased frequency of *ga733.3*(8/63 vs. 1/14), *muc-1*(10/63 vs. 1/14), *spdef*(7/58 vs. 0/25) and *mgb1*(5/55 vs. 0/25). It is notable, that Zhong et al. (1999) demonstrated a high frequency of *ga733.3*expression in healthy subjects (40%; 16/40) \[[@B20]\]. However, this study did not include any immunomagnetic processes to eliminate haematogenous cells. Another investigation of Rao et al. (2005) revealed a decrease of *ga733.3*expression in CTC as compared to *ga733.3*expression in tumour tissues, proposing a mechanism through which cells loose adhesion to enter circulation. Yet, this study did not include control subjects \[[@B22]\].

*Muc-1*is described as a widely expressed gene in cells of epithelial origin. The literature shows controversial results regarding *muc-1*. On the one hand, Raynor et al. (2002) demonstrated that *muc-1*transcribes a surface molecule, which was found in human non-malignant cells. Hence, a putative marker feature was denied in this investigation \[[@B43]\]. On the other hand, Felton et al. (2004) verified *muc-1*expression in 8 of 9 advanced cases of BC, whereas only 1 of 11 healthy controls showed a positive expression. Moreover, they confirmed the expression of *muc-1*in nonmalignant peripheral lymphocytes \[[@B44]\]. Our investigation revealed 15.9% positive expression in BC samples but only 7% in healthy controls. Notably, former approaches did not include any immunomagnetic separation method and were performed in restricted numbers of patients. *Spdef*(*SAM pointed domain-containing ETS transcription factor, synonym PDEF*) is a transcription factor involved in processes like cell proliferation, differentiation and invasion. It is mainly expressed in tissues with high fraction of epithelial cells. Recently, Ghadersohi et al. (2001) described higher expression of *spdef*in BC tissue as compared to healthy breast specimens \[[@B28]\]. In line with those results, we did not observe any positive results in the control group.

Most notably, in 2005, Van\'t Veer et al. emphasized the importance of gene expression profiling of multiple genes in BC, since single or double gene determination did not show satisfactory accuracy \[[@B45]\]. Here we demonstrate, that method-overlapping (mPCR and realtime-PCR) grouping of 4 genes, *ga733.3, muc-1, spdef*and *mgb1*exposes a positive result in 23.8% of our BC patient population. Fourfold profile (*ga733.3*\* *muc-1*\**spdef*\**mgb1*) of controls levelled off at 14.3%. To the best of our knowledge, our study represents the first investigation of fourfold gene profiles reported in the literature.

Taken together, our study shows that the single genes *ga733.3, muc-1*and the gene profiles *ga733.3*\* *muc-1*and *ga733.3*\*2*muc-1*\**mgb1*\**spdef*can serve as markers for the detection of CTC in BC. Multigene analyses revealed highly positive levels in BC patients. Our study indicates that not single gene analyses but subtle patterns of multiple genes leads to rising accuracy and low loss of specificity in detection of BC cases

Yet, further studies are needed to better characterize CTC and to better understand metastatic processes in BC. Prospective studies with a larger patient populations and investigations of other target genes may identify aggressive profiles of BC and may influence therapeutic decisions.
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